Athira Pharma’s Post

Randomized clinical trial supports the importance of fibrillar amyloid reduction in multiple Alzheimer disease-related processes of neuroinflammation and neurodegeneration in CSF and plasma in dominantly inherited Alzheimer disease. https://ja.ma/4cdq5El

🧠 Exciting New Research on Psilocybin for Huntington's Disease Treatment! 🌱 The URNCST Journal is excited to share a new research protocol exploring the potential of psilocybin to treat Huntington's Disease (HD), a devastating neurodegenerative disorder that causes progressive neuron death in the brain. In this publication, the authors propose using psilocybin, known for its neuroprotective, neurotrophic, and neuroplastic properties, to reduce neuron loss and improve motor functions in zQ175 knock-in (KI) mice, which model HD. By analyzing brain samples and motor control through behavioral tests, they aim to uncover whether psilocybin can slow HD progression. 📈 Expected results: - Decreased neuronal death 🧠 - Increased synaptic density 🌿 - Improved motor control 🏃 If successful, this study could pave the way for future clinical trials and potentially improve the quality of life for those affected by Huntington's Disease. Read the full article here: https://lnkd.in/g6jsTCNe #URNCST #ResearchProtocol #HuntingtonsDisease #psilocybin #SynapticDensity #5HT2AReceptor

Determining which mechanisms cause changes in neuronal excitability can be challenging, especially in heterogeneous diseases such as ALS. By looking at patterns of changes in excitability, we can get better insights into these mechanism at the individual patient level. In our newly published article in Brain, we develop a novel method to study these “excitability patterns”. This approach could help to efficiently study target engagement in clinical trials and could improve our understanding of which neuronal mechanisms contribute to the neurodegenerative cascade. Most notably, our approach uncovered a novel link between altered slow-potassium channel function and the progression rate of patients with ALS. For those interested, you can read the article here: https://lnkd.in/eXW9BKeB

Another publication with real-world evidence (RWE) generated from Atropos Health. "Inflammatory vaginitis in women with multiple sclerosis: a retrospective analysis of B-cell depleting therapy compared to other disease modifying therapies" was published in "Multiple Sclerosis and Related Disorders." The paper explores the use of major B cell therapies for Multiple Sclerosis (e.g. rituximab, ocrelizumab, ofatumumab) and the risk of vaginitis in women with MS. Co-authors Sarah Esther Conway, MD, Gavin Hui, MD, Will Pike, MD, Cory Dodson, and Kristin Galetta. Access the full paper: https://lnkd.in/etS5_tsZ #RealWorldEvidence #RWE #AtroposHealth #MultipleSclerosis #BCellDepletingTherapy #DiseaseModifyingTherapies #BCellTherapies #Rituximab #Ocrelizumab #Ofatumumab #Vaginitis

Let Atropos Health help you with your RWE studies…we can turn this data and reporting around in record time (48 hours)!

Interesting developments in the Phase 3 trials of Aducanumab shed light on the high risk of Amyloid-Related Imaging Abnormalities in APOE carriers. The findings hold significant implications for our understanding of Alzheimer's disease. #alzheimersresearch #healthcareinnovation "

Today is World Alzheimer's Day, a day to raise awareness for the world’s most common neurodegenerative disorder. More than 6.7 million Americans are living with Alzheimer’s today and by 2050, that number is expected to reach nearly 14 million. Our seventh flight to the #ISS National Laboratory in early 2025 will continue our team’s study of neurodegeneration in space to observe cell interactions in a way not possible on Earth. The study may provide valuable new insight into how neurodegenerative diseases develop, accelerate biomarker discovery for early diagnosis, and open the door to new cell and drug therapy options for Alzheimer’s and other neurodegenerative diseases. Learn more and support NSCF today! #WorldAlzheimersDay #alzheimers #WorldAlzMonth Dr. Paula Grisanti

Fosgonimeton demonstrated encouraging pro-cognitive effects in clinical trials, supporting its continued development for the treatment of #Parkinsons Disease.     On the heels of #ADPD2024, Andrea Lobo, Ph.D. of Parkinson's News Today highlights our SHAPE Phase 2 #fosgonimeton results, its mechanism of action, and supporting preclinical data in her recent article.     Read it here: https://bit.ly/4awTtoC

I am glad to share with you our new collaborative publication unveiling a set of molecules important in neuronal and glia inflammation associated with the conversion from mild cognitive impairment to Alzheimer’s disease, by a machine learning-based approach. 👉 https://lnkd.in/dM3esgWC #humanresearch #oleamide #MCI #Alzheimer #machinelearning Consiglio Nazionale delle Ricerche

🎉🎉🎉 New special issue "Mitochondria in Glia-neuron Crosstalk" launched online!!! Submission Deadline: January 31, 2025 Topics of interest include but are not limited to: · Molecular signaling pathways mediating glia-neuron interactions · Influence of glial cells on synaptic transmission and plasticity · Role of mitochondria in neuroinflammation and neuroprotection · Mitochondrial dysfunction in neurodegenerative disorders such as Alzheimer's, Parkinson's, and Huntington's disease · Novel therapeutic strategies targeting glial cells and mitochondria for neurological conditions · Molecular mechanisms of glia-neuron communication · Impact of glial dysfunction on neuronal health and disease · Role of mitochondria in synaptic plasticity and neurotransmission · Mitochondrial dynamics in glial cells and neurons · Neurodegenerative diseases and mitochondrial dysfunction Please feel free to contact me if you are interested in this special issue. https://lnkd.in/gxEurFjx